Virus News and Research

Latest Virus News and Research

Praxis extends patient recruitment services for international HCV study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, is extending patient recruitment services to a top 20 pharmaceutical company for an international Hepatitis C Virus study. The study explores an investigational drug's effectiveness for this condition affecting almost 4 million Americans.

31 Mar 2010

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

GeoVax Labs, Inc., a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is now allowed by the FDA to begin a phase 1 clinical trial for GeoVax's therapeutic vaccine, which is intended as a treatment for individuals infected with HIV. The company will begin a non-blinded study in HIV infected individuals who started drug treatment during their first year of infection.

30 Mar 2010

New therapeutic approaches against lymphoid tumors

Helmholtz Zentrum M-nchen has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

30 Mar 2010

Resurgence of mumps orchitis among teenage boys and young men

Urologists at a leading Irish hospital have reported an alarming increase in the number of teenage boys and young men developing mumps orchitis, in a paper published in the April issue of the urology journal BJUI.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Potential new target for treating HCV infection

A team of scientists including University of Utah researchers has discovered that binding of a potent inhibitor of the hepatitis C virus to the genetic material of the virus causes a major conformational change that may adversely affect the ability of the virus to replicate.

30 Mar 2010

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

GenVec, Inc. announced today that it is discontinuing its Phase 3 clinical trial of TNFerade™ in patients with locally advanced pancreatic cancer based on results of an interim analysis. This interim analysis of overall survival, conducted after the 184th death (two-thirds of total expected events), was designed to determine whether the study should continue.

30 Mar 2010

Also in Global Health News: H1N1; USAID's Global Pulse; Rotavirus vaccine; Uzbek doctors; Zimbabwe development; Malaria vaccine

WHO flu chief Keiji Fukuda on Monday announced that a group of 29 independent scientists and public health experts has been formed to evaluate the response of the organization and national governments to the emergence of H1N1 (swine flu), the Associated Press reports. According to Fukuda, the committee will hold its first meeting April 12-14 (3/29).

29 Mar 2010

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine.

29 Mar 2010

Helmholtz Zentrum München, SIRION BIOTECH partner to develop new therapeutic approaches against lymphoid tumors

Helmholtz Zentrum München has launched a new cooperative project with SIRION BIOTECH GmbH in Martinsried to develop new therapeutic approaches against lymphoid tumors. With a two-year grant from the Federal Ministry for Economics and Technology, the two partners will seek to further develop lentiviral vector systems to better understand the disease mechanisms of this cancer form and to devise approaches for treatment.

29 Mar 2010

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Inovio Biomedical Corporation today reported financial results for the quarter and year ended December 31, 2009.

29 Mar 2010

Rift Valley Fever on the rise

Rift Valley fever (RVF) is a viral infection transmitted by mosquitoes that mainly affects animals and livestock but may also infect humans. It can lead to high rates of death and disease. While mild forms of the disease can cause fever, muscle and joint pains, headaches, loss of appetite etc., the severe form can affect the eyes, cause meningitis, severe bleeding and even death.

29 Mar 2010

Study provides new clues to obesity epidemic

In a newly published study, scientists from The Scripps Research Institute have shown for the first time that the same molecular mechanisms that drive people into drug addiction are behind the compulsion to overeat, pushing people into obesity.

29 Mar 2010

Antiviral treatment may lead to drug-resistant H1N1 virus: NIAID

Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after less than two weeks on therapy, report doctors from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

27 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

State HIV programs face cuts, CDC notes high prevalence in young African-Americans, gay men

NPR's Shots blog: "As states struggle with budget shortfalls, many are looking to trim costs by chopping health spending. And funding for HIV/AIDS programs has been a prime target. A proposed budget in South Carolina would eliminate funding for HIV/AIDS prevention and for help with buying drugs to treat the disease. 'South Carolina is thought to be the first state in the nation to propose the elimination of its entire HIV/AIDS budget,' the newspaper The State reported. Elsewhere, HIV/AIDS funding has been under pressure for a while.

27 Mar 2010

Study: Surgical masks prevented hospital staff from acquiring H1N1

The effectiveness of ordinary surgical masks as opposed to respirators in protecting health care workers against the 2009 H1N1 influenza virus has been the subject of debate. An observational study published in the April 1, 2010 issue of Clinical Infectious Diseases, available online, suggests that surgical masks are just as effective as respirators in this regard.

26 Mar 2010

Common beliefs on the spread of sexually transmitted diseases may not apply to HPV: Study

A small new study suggests that some common beliefs about the spread of sexually transmitted diseases may not apply to human papillomavirus, also known as HPV.

26 Mar 2010

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

Argos Therapeutics today announced the presentation of data from the Phase 2a trial of AGS-004, providing information on rebound viral genetic diversity in HIV patients treated with the personalized immunotherapy following antiretroviral therapy (ART) interruption. The data were discussed in a poster session at the Keystone Symposia Global Health Series HIV Vaccines meeting, held March 21-26, 2010 in Banff, Canada.

26 Mar 2010

Virus News and Research

Latest Virus News and Research

Praxis extends patient recruitment services for international HCV study

FDA allows GeoVax Labs to commence phase 1 clinical trial for HIV/AIDS therapeutic vaccine

New therapeutic approaches against lymphoid tumors

Resurgence of mumps orchitis among teenage boys and young men

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

Preclinical study of DAS181 for treatment and prevention of ILI published

Potential new target for treating HCV infection

GenVec announces discontinuation of TNFerade PACT trial for pancreatic cancer

Also in Global Health News: H1N1; USAID's Global Pulse; Rotavirus vaccine; Uzbek doctors; Zimbabwe development; Malaria vaccine

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Helmholtz Zentrum München, SIRION BIOTECH partner to develop new therapeutic approaches against lymphoid tumors

Inovio Biomedical's total revenue increased to $2.6M for quarter ended December 31, 2009

Rift Valley Fever on the rise

Study provides new clues to obesity epidemic

Antiviral treatment may lead to drug-resistant H1N1 virus: NIAID

WinRho SDF for ITP: Cangene announces new safety information

State HIV programs face cuts, CDC notes high prevalence in young African-Americans, gay men

Study: Surgical masks prevented hospital staff from acquiring H1N1

Common beliefs on the spread of sexually transmitted diseases may not apply to HPV: Study

Data on Argos Therapeutics' Phase 2a AGS-004 immunotherapy trial presented at Banff HIV Vaccines meeting

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

How microRNA is transforming science: From discovery to diagnostics

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Newsletters you may be interested in